ShanghaiJune 15, 2026 /PRNewswire/ — The 2026 European Hematology Association (EHA) Annual Congress officially opened on June 11 in Stockholm, Sweden. As a major event for hematology professionals worldwide, the EHA Congress covers all aspects of hematology research, attracting over 10,000 experts from more than 100 countries each year to share and discuss innovative concepts and the latest scientific and clinical research findings in hematology.
At this congress, Hengrui Medicine presented over 10 innovative drug research findings, involving products such as the thrombopoietin (TPO) receptor agonist Hetrombopag Olamine Tablets (Hengqu®), the novel highly selective oral EZH2 inhibitor Zemetostat Tablets (Airuijing®), Ivarmacitinib Sulfate Tablets (Aisuda®), and the complement factor B inhibitor Licampor Fumarate Capsules (development code: HRS-5965), among others[1].
01. Abstract Number: PB4453
Prophylactic Hetrombopag for Prevention of Cancer Therapy-Induced Thrombocytopenia in Gastrointestinal Malignancies: Results from an Ongoing Single-Arm Prospective Study
Prophylactic Hetrombopag for Prevention of Cancer Therapy-Induced Thrombocytopenia in Gastrointestinal Malignancies: Results from an Ongoing Single-Arm Prospective Study
Key Information:
This single-arm prospective study planned to enroll 40 patients with gastrointestinal malignancies to explore the efficacy and safety of hetrombopag in preventing cancer therapy-induced thrombocytopenia (CTIT). Enrolled patients had a nadir platelet count of 75-125×10⁹/L in the previous chemotherapy cycle, accompanied by at least one high-risk factor for bleeding. Patients received hetrombopag 7.5 mg/day for 14 days starting on the day of chemotherapy. As of February 5, 2026, a total of 25 patients were included in the efficacy and safety analysis. The proportion of patients with platelet count >75×10⁹/L on Day 14 was 76% (19/25); on Day 21, the proportions of patients with platelet counts >75×10⁹/L and ≥100×10⁹/L were 83% (20/24) and 79% (19/24), respectively. The incidence of chemotherapy delay ≥4 days in the next cycle was 4% (1/25), and the incidence of platelet count <50×10⁹/L was 8% (2/25). In terms of safety, no treatment-related adverse events were reported during the study period.
The study suggests that prophylactic use of hetrombopag may help maintain platelet levels in patients with gastrointestinal malignancies, reduce chemotherapy delays, and has a favorable safety profile.
02. Abstract Number: PB4283
Exploration of the Treatment and Economic Evaluation of Hetrombopag Plus Recombinant Human Thrombopoietin for Chemotherapy-Induced Thrombocytopenia in Lymphoma
Exploration of the Treatment and Economic Evaluation of Hetrombopag Plus Recombinant Human Thrombopoietin for Chemotherapy-Induced Thrombocytopenia in Lymphoma
Key Information:
This retrospective study included 269 lymphoma patients with grade 3-4 CIT treated at a single center between December 2023 and July 2025. Patients received hetrombopag (7.5 mg once daily), eltrombopag (75 mg once daily), rhTPO (recombinant human thrombopoietin, 300 U/kg once daily), TPO-RA (hetrombopag or eltrombopag) combined with rhTPO, or no thrombopoietic agents (control group). Results showed that all thrombopoietic treatments significantly increased platelet counts, with the hetrombopag+rhTPO group achieving the fastest platelet recovery. Mean times to reach ≥50, ≥75, and ≥100×10⁹/L were 4.0, 5.2, and 6.6 days, respectively, superior to hetrombopag monotherapy (5.4, 7.3, 9.3 days) and rhTPO monotherapy (5.6, 7.3, 9.5 days). Platelet recovery with hetrombopag monotherapy was comparable to rhTPO monotherapy. Compared with the control group, bleeding events and platelet transfusion rates were significantly reduced in all treatment groups. The transfusion rate in the hetrombopag monotherapy group was comparable to that in the hetrombopag+rhTPO group, and both were superior to the rhTPO monotherapy group. In 88 patients who underwent immune profiling, levels of Treg cells, IL-6, and IL-10 significantly decreased after platelet recovery to ≥100×10⁹/L.
The study indicates that in patients with grade 3-4 CIT due to lymphoma treatment, hetrombopag 7.5 mg/day achieves platelet recovery comparable to rhTPO; combining with rhTPO further accelerates platelet recovery.
03. Abstract Number: PB4291
Hetrombopag Combined with Prednisone as First-line Therapy for Primary Immune Thrombocytopenia (ITP)
Hetrombopag Combined with Prednisone as First-line Therapy for Primary Immune Thrombocytopenia (ITP)
Key Information:
This single-center, single-arm, exploratory phase II clinical study enrolled 49 adult patients with confirmed primary ITP. Inclusion criteria were platelet count <30×10⁹/L, or <50×10⁹/L with significant bleeding (bleeding score ≥2). Patients received prednisone 1 mg/kg/day (maximum 80 mg/day) combined with hetrombopag for 8 weeks. Hetrombopag was initiated within 7 days of starting steroids at a starting dose of 5 mg/day; if platelet count remained <50×10⁹/L after 2 weeks, the dose was increased to 7.5 mg/day. Prednisone was tapered as soon as response was achieved and discontinued within 6-8 weeks; if no response was seen after 2 weeks, it was discontinued. As of December 31, 2025, enrolled patients were 63.3% female, 73.5% newly diagnosed ITP, median age 58.0 years, and median baseline platelet count 11×10⁹/L. Primary endpoint: The proportion of patients with sustained response at 26 weeks post-treatment was 84.1%. After 8 weeks of treatment, the overall response rate (defined as two consecutive measurements at least 7 days apart with platelet count ≥30×10⁹/L, doubling from baseline, and no bleeding) reached 91.7%, the complete response rate (defined as two consecutive measurements at least 7 days apart with platelet count ≥100×10⁹/L, doubling from baseline, and no bleeding) was 54.2%, and the median time to response was only 5 days. In terms of safety, no treatment-related thrombotic events or hepatotoxicity were observed.
The study shows that hetrombopag combined with prednisone as first-line therapy for primary ITP demonstrates rapid platelet response with 84.1% of patients achieving sustained response at 26 weeks post-treatment, significantly reducing glucocorticoid exposure dose and duration, lowering bleeding risk, and having a favorable safety profile. It has the potential to become a first-line treatment strategy for primary ITP, pending further validation in randomized controlled trials.
04. Abstract Number: PS2443
Efficacy and Safety of Hetrombopag in Increasing Platelet Counts in Patients With Hepatocellular Carcinoma Undergoing Hepatectomy: A Randomized, Placebo-Controlled Study
Efficacy and Safety of Hetrombopag in Increasing Platelet Counts in Patients With Hepatocellular Carcinoma Undergoing Hepatectomy: A Randomized, Placebo-Controlled Study
Key Information:
This randomized, placebo-controlled study enrolled a total of 69 patients (FAS set), of which 62 entered the per-protocol set (PPS) and were included in the efficacy analysis (34 in the hetrombopag group, 28 in the placebo group). Baseline characteristics were balanced between the two groups, including median age (57.0 years vs. 59.3 years), proportion of males (76.5% vs. 64.3%), and baseline platelet count (mean 65.0±13.2×10⁹/L vs. 63.5±10.9×10⁹/L). Primary endpoint: 58.8% (20/34) of patients in the hetrombopag group did not require platelet transfusion or other platelet-boosting interventions, compared to 21.4% (6/28) in the placebo group (P=0.003). No patients in either group required platelet transfusion (0 vs. 0). The proportion of patients requiring other platelet-boosting interventions was lower in the hetrombopag group than in the placebo group (41.2% vs. 78.6%). Secondary endpoint: A higher proportion of patients in the hetrombopag group achieved preoperative platelet count ≥80×10⁹/L (58.8% vs. 21.4%). The mean increase in platelet count from baseline before hepatectomy was greater in the hetrombopag group than in the placebo group (15.6±16.6×10⁹/L vs. 5.6±15.5×10⁹/L, P=0.06). No serious adverse events were reported.
Conclusion: In patients with hepatocellular carcinoma and thrombocytopenia scheduled for hepatectomy, compared with placebo, hetrombopag significantly reduced the need for platelet transfusion and other platelet-boosting interventions, with a favorable safety profile.
05. Abstract Number: PF687
Efficacy and Safety of HRS-5965 versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Multicenter, Randomized, Open-Label, Active-Controlled Phase 3 Trial
Efficacy and Safety of HRS-5965 versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Multicenter, Randomized, Open-Label, Active-Controlled Phase 3 Trial
Key Information:
This multicenter, randomized, open-label, active-controlled phase 3 study enrolled 78 PNH patients who had not previously received complement inhibitors. Patients were randomized 1:1 to receive oral HRS-5965 (50 mg twice daily) or intravenous eculizumab for 24 weeks. After 24 weeks, the primary endpoint (achieving hemoglobin [Hb] ≥12 g/dL in at least 3 of 4 measurements between weeks 18 and 24, with no red blood cell transfusion after week 2) was met by a significantly higher proportion of patients in the HRS-5965 group compared to the eculizumab group: 70.0% (28/40) vs. 11.1% (4/36), with a rate difference of 57.4% (95% CI: 39.6-75.2%; P<0.0001). The key secondary endpoint (Hb increase ≥2 g/dL from baseline) was also significantly better in the HRS-5965 group: 95.0% (38/40) vs. 55.6% (20/36), with a rate difference of 39.2% (95% CI: 20.9-57.4%; P<0.0001). The proportion of patients achieving transfusion avoidance after week 2 was significantly higher in the HRS-5965 group: 100% vs. 86.1% (P=0.0149). The mean increase in Hb from baseline was significantly greater in the HRS-5965 group compared to the eculizumab group (LS mean difference: 2.61 g/dL, 95% CI: 1.72-3.49; P<0.0001). Improvement in FACIT-Fatigue score was also significantly better in the HRS-5965 group (LS mean difference: 4.19, P=0.0001). Regarding changes in reticulocyte count, the HRS-5965 group showed a significant decrease, while the eculizumab group showed an increasing trend (LS mean difference: -161.37×10⁹/L, P<0.0001). In terms of safety, no major adverse vascular events (MAVEs) occurred in either group. Adverse events during treatment were manageable.
The study demonstrates that in PNH patients who have not previously received complement inhibitors, oral HRS-5965 is significantly superior to eculizumab in improving hemoglobin levels, reducing transfusion dependence, and improving quality of life, with a manageable safety profile. As a novel oral factor B inhibitor, HRS-5965 has the potential to provide a new treatment option for PNH patients.
06. Abstract Number: PF688
Efficacy and Safety of HRS-5965 in Paroxysmal Nocturnal Hemoglobinuria Patients with Persistent Anemia despite Stable C5 Inhibitor Therapy: A Multicenter, Single-Arm, Open-Label Phase 3 Study
Efficacy and Safety of HRS-5965 in Paroxysmal Nocturnal Hemoglobinuria Patients with Persistent Anemia despite Stable C5 Inhibitor Therapy: A Multicenter, Single-Arm, Open-Label Phase 3 Study
Key Information:
This multicenter, single-arm, open-label phase 3 study enrolled 39 patients with confirmed PNH who had persistent anemia (hemoglobin [Hb] <10 g/dL) despite stable C5 inhibitor therapy (eculizumab/covarlizumab) for at least 6 months prior to enrollment. Patients received oral HRS-5965 50 mg twice daily for 24 weeks. After 24 weeks of treatment, the primary endpoint (achieving Hb ≥12 g/dL in at least 3 of 4 measurements between weeks 18 and 24, with no red blood cell transfusion after week 2) was met by 69.2% of patients (95% CI: 52.4-83.0%). The key secondary endpoint (Hb increase ≥2 g/dL from baseline) was achieved by 92.3% of patients (95% CI: 79.1-98.4%). All patients (100.0%; 95% CI: 91.0-100.0%) achieved transfusion avoidance after week 2. Mean Hb increased by 4.95 g/dL from baseline (95% CI: 4.66, 5.24), mean reticulocyte count decreased by 170.18×10⁹/L (95% CI: -177.13, -163.23), and mean FACIT-Fatigue score improved by 8.75 points (95% CI: 8.23-9.26). In terms of safety, no major adverse vascular events (MAVEs) were reported. Adverse events during treatment were manageable.
The study demonstrates that HRS-5965 provides significant clinical benefit in PNH patients with persistent anemia despite C5 inhibitor therapy, improving hemoglobin levels, achieving transfusion independence, and enhancing quality of life, with a favorable safety profile. As a novel oral factor B inhibitor, HRS-5965 has the potential to become a new option in the PNH treatment landscape.
07. Abstract Number: PF1057
Phase Ib Study of SHR0302 plus SHR2554 in Relapsed/Refractory Peripheral T-Cell Lymphoma: Safety Run-in and Initial Efficacy
Phase Ib Study of SHR0302 plus SHR2554 in Relapsed/Refractory Peripheral T-Cell Lymphoma: Safety Run-in and Initial Efficacy
Key Information:
This phase Ib safety run-in portion of a phase Ib/II study enrolled 14 adult patients with histologically confirmed relapsed/refractory peripheral T-cell lymphoma (PTCL) (median prior lines of therapy: 2), including 4 with PTCL-NOS, 8 with AITL, and 2 with ALCL. Patients received ivarmacitinib 4 mg (n=9) or 8 mg (n=5) once daily, combined with a fixed dose of zemetostat 300 mg twice daily, in 28-day cycles. No dose-limiting toxicities (DLTs) were observed in either dose group during cycle 1. Adverse events during treatment were manageable. As of January 28, 2026, 10 patients were evaluable for efficacy (6 in the 4mg group, 4 in the 8mg group). The best ORR was 40.0% (4/10), DCR was 80.0% (8/10), including 2 CR and 2 PR. The 4mg group met the predefined criteria to continue the study (≥2 CR/PR among the first 6 patients in stage 1), with an ORR of 50.0% (3/6), CR rate of 33.3% (2/6), and DCR of 83.3% (5/6). The 8mg group had an ORR of 25.0% (1/4) and DCR of 75.0% (3/4), with stage 1 enrollment still ongoing. The recommended phase II dose (RP2D) has not yet been determined and will be selected based on overall safety and efficacy results from each dose group.
The study indicates that ivarmacitinib combined with zemetostat has a manageable safety profile and demonstrates preliminary anti-tumor activity in relapsed/refractory PTCL.
Reference Source:
[1]https://library.ehaweb.org/eha/#!*menu=6*browseby=3*sortby=2*ce_id=2934*featured=20117
Disclaimer:
1. This news release is intended to share academic frontiers and is for reference by healthcare professionals for academic purposes only. It is not an advertisement.
2. Hengrui Medicine does not recommend any drug and/or indication.
3. The information in this news release is for reference only. Please follow the advice or guidance of a doctor or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific condition and in accordance with the drug prescribing information.